Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients
Go back to Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients| CACI INTERNATIONAL CLA (NASDAQ: CAI) | Delayed: 17.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.60 | 52 Week High | $11.53 | |||
| Open | $17.60 | 52 Week Low | $4.83 | |||
| Day High | $17.60 | P/E | 5.97 | |||
| Day Low | $17.60 | EPS | $2.95 | |||
| Volume | 245 | |||||
